Skip to main content

Table 6 Intraprostatic FDG uptake as a predictor of the predicted 5-year progression-free survival by CAPRA-S and MSKCC nonograms

From: FDG-PET/CT for pre-operative staging and prognostic stratification of patients with high-grade prostate cancer at biopsy

 

CAPRA-S*

MSKCC †

 

Median % (25th – 75th percentile)

P -value

Median % (25th – 75th percentile)

P -value

Clinical reporting

IPFU-

70.2 (26.7 – 85.2)

0.008

91.5 (77.0 – 97.0)

0.004

IPFU+

25.9 (0.0 – 42.5)

 

59.0 (42.0 – 88.0)

 

Blinded reading

IPFU- (Score 0 or 1)

70.2 (34.2 – 91.0)

0.017

93.0 (81.0 – 97.5)

0.010

IPFU+ (Score 2 to 4)

26.9 (0.0 – 63.3)

 

73.0 (45.3 – 89.8)

 

Quantitative analysis

IPFU- (SUVmax < 4.0)

70.2 (26.7 – 85.2)

0.030

91.5 (72.8 – 97.0)

0.020

IPFU+ (SUVmax ≥ 4.0)

25.9 (0.0 – 42.5)

 

72.0 (45.0 – 89.0)

 
  1. FDG = 18F-fluorodeoxyglucose; IPFU = intraprostatic FDG uptake; IPFU- = IPFU-negative; IPFU + = IPFU-positive; SUVmax = maximum standardized uptake value.
  2. *University of California, San Franciso Cancer of the Prostate Risk Assessment score: Post-Radical Prostatectomy nomogram.
  3. †Memorial Sloan-Kettering Cancer Center post-radical prostatectomy nomogram.
Back to article page

Cancer Imaging

ISSN: 1470-7330

Contact us